Maqola

Extensively Hydrolyzed Hypoallergenic Infant Formula with Retained T Cell Reactivity

Raphaela FreidlCenter for Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, A-1090 Vienna, AustriaVictoria GaribInternational Center of Molecular Allergology, Ministry of Innovation Development, Tashkent 100174, UzbekistanBirgit LinhartCenter for Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, A-1090 Vienna, AustriaElisabeth M. HaberlHiPP GmbH & Co. Vertrieb KG, 85276 Pfaffenhofen, GermanyIsabelle MaderHiPP GmbH & Co. Vertrieb KG, 85276 Pfaffenhofen, GermanyZsolt SzépfalusiMedical University of ViennaKlara SchmidthalerMedical University of ViennaNikos DouladirisAllergy Department, 2nd Pediatric Clinic, National & Kapodistrian University of Athens, 11527 Athens, GreeceА Н ПампураDepartment of Allergology and Clinical Immunology, Research and Clinical Institute for Pediatrics Named after Yuri Veltischev at the Pirogov Russian National Research Medical University of the Russian Ministry of Health, 117997 Moscow, RussiaEvgeniy E. VarlamovDepartment of Allergology and Clinical Immunology, Research and Clinical Institute for Pediatrics Named after Yuri Veltischev at the Pirogov Russian National Research Medical University of the Russian Ministry of Health, 117997 Moscow, RussiaTatiana Sergeevna LepeshkovaDepartment of Faculty Therapy, Endocrinology, Allergology and Immunology, Ural State Medical University, 620014 Ekaterinburg, RussiaЕ. К. BeltyukovDepartment of Faculty Therapy, Endocrinology, Allergology and Immunology, Ural State Medical University, 620014 Ekaterinburg, RussiaВ. В. НаумоваDepartment of Faculty Therapy, Endocrinology, Allergology and Immunology, Ural State Medical University, 620014 Ekaterinburg, RussiaStyliani ΤakaAllergy Department, 2nd Pediatric Clinic, National & Kapodistrian University of Athens, 11527 Athens, GreeceDina NosovaOlga GuliashkoMichael KundiDepartment for Environmental Heath, Center for Public Health, Medical University of Vienna, A-1090 Vienna, AustriaAlina KiyamovaInternational Center of Molecular Allergology, Ministry of Innovation Development, Tashkent 100174, UzbekistanStefani KatsamakiInternational Center of Molecular Allergology, Ministry of Innovation Development, Tashkent 100174, UzbekistanRudolf ValentaNRC Institute of Immunology FMBA of Russia, 119049 Moscow, Russia

2022en

Ochiq kirishOltin

Litsenziya: cc-by

ABI

Annotatsiya

Background: Immunoglobulin E (IgE)-mediated cow’s milk allergy (CMA) can be life-threatening and affects up to 3% of children. Hypoallergenic infant formulas based on hydrolyzed cow’s milk protein are increasingly considered for therapy and prevention of cow’s milk allergy. The aim of this study was to investigate the allergenic activity and ability to induce T cell and cytokine responses of an infant formula based on extensively hydrolyzed cow’s milk protein (whey) (eHF, extensively hydrolyzed formula) supplemented with Galactooligosaccharides (GOS) and Limosilactobacillus fermentum CECT5716 (LF) to determine its suitability for treatment and prevention of CMA. Methods: eHF and standard protein formula based on intact cow’s milk proteins (iPF) with or without Galactooligosaccharide (GOS) and Limosilactobacillus fermentum CECT5716 (LF) were investigated with allergen-specific antibodies and tested for IgE reactivity and allergenic activity in basophil degranulation assays with sera from cow’s milk (CM)-allergic infants/children. Their ability to stimulate T cell proliferation and cytokine secretion in cultured peripheral blood mononuclear cells (PBMC) from CM-allergic infants and children was studied with a FACS-based carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution assay and xMAP Luminex fluorescent bead-based technology, respectively. Results: An eHF supplemented with GOS and LF exhibiting almost no IgE reactivity and allergenic activity was identified. This eHF induced significantly lower inflammatory cytokine secretion as compared to an intact protein-based infant formula but retained T cell reactivity. Conclusions: Due to strongly reduced allergenic activity and induction of inflammatory cytokine secretion but retained T cell reactivity, the identified eHF may be used for treatment and prevention of CMA by induction of specific T cell tolerance.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.3390/nu15010111

Iqtiboslar va manbalar

0 ta iqtibos29 ta foydalanilgan manba